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cardiac catheterization, measurements of related hemodynamic parame-
ters and EMB. Myocardial norepinephrine (MNEC), epinephrine (MEC), and
dopamine (MDC) concentrations were assayed using cateohol-O-methyl-
tranaferase radioenzymatic method and the obtainad values were expressed
as nglg of fresh tissue. The following mrrelations with LV parameters were
found (“”ps 0.01):
6PM DCM HCM
MNEC MEC MDC MNEC MEC MDC MNEC MEC MDC
LVEF 0.34 0.08 –0.02 0.89** 0.S68’ 0.02 0.71;” 0.80”” 0.12
LVdp/J 0.33 –0,18 0.09 0.67”’ 0.74”” 0.07 0.s0$” 0.77’” 0.07
I.vEDP –0.09 –0.13 –0.23 –0.79”” –0.75”” –0.11 0.16 0.05 –0.31-----
PCWP -0.22 0:17 –0.14 –0.63”” –0.76** –0.07 0.02 –0.03 –0.17
Furthermore, the comparison of MCC among investigated groups re-
vealed the following differences:
BPM DCM HCM
MNEC 415.4 * 71.1” 262.2 & 6S.9* 781.0+ 125.1”
MEC 57.3 * 4.6* 36.9 + 7.1* 91.3* 13.1”
MDC 76.6 ~ 9.2 ns 72.6 + 12.1 ns 76.1 + 9.3 ns
lp <0,01 (BPM VS.DCM); ‘p s 0,01 (HCM VS,BPM);*p s 0.01 (HCM VS.DC).
In mnclusion, these date suggest that MNEC and MEC strongly correlate
with LV hemodynamic parameter in DCM and HCM, but MDC does not.
Moreover, highest MNEC and MEC were demonstrated in the HCM group,
while their values were significantly increased in BPM pts in comparison to
DCM group.
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m7971 Primary Angioplasty Vsraus Thrombolysis With tPAin Anterior Myocardial Infarction: Resulta From a
Single Csntsr Trial
E. Garcia, J. Elizega, J. Soriano, M. Abeytua, J. Betas, A. Fernandez,
R. Rubio, E. Lopez, J. Lopez-Sendon, J.L. Delcan. Ffospita/Gregorio
Marar%n, Madrid, Spain
Although the special benefit of primary angioplasty (PA)compared withtPA in
patients (P) with anterior myocardial infarction (AMI) observed in a previous
trial haa been challenged in a larger recent study, no randomized trials have
been conducted including only P with AMI. We have recently concluded a
study comparing PAwith tPA in Pwith AMI, who were admitted to the hospital
no later than 5 h from the onset of pain. A total of 189 P (95 treatad with
PA and 94 with tPA) were included. Both groups were balanced with similar
baseline characteriatica. All the P received aspirin (126-325 mg/day). P in
the PA group received a bolua of 10.000 IU of heperin followed by 1000 IU/h
for 46 h and Pin tPA group received only Im ILf/hfor 48 h. The time from
oneat of pain to treatment wee 214+7 minutes for PAand 198 + 7fortPA (p
= NS). Permeability of the infarct relatad arIety (left anterior descanding-1-AD)
was teatad in both groups by cardiac catheterization (CC) before discharge.
The major adverse events in both groups are the following:
Mortality Reinfarction CVA
PA 3.1% 4.2% 3.2”h
T 10.6”A 4.2% o
. mm NS NS
Recurrent iechemia was present in 14.8% of Ptreated with PAand 30.8%
of P with tPA (p = 0.009). Angioplasty of the LAD was performed in 9.57.
of P treated with PA and 34% with tPA (p c 0.00001). TIMI Ill at the CC
prediacharge was present in 66% of the PA P and 58% of the tPA (p =
0.0004), and reaidual stenosis of the IAD was 34% after PA and 69% after
tPA (p < 0.00001).
In cone/usion:A study conducted only in P with AMI in a single center has
proved a reduction in mortality, recurrent ischemia, residuai stenosis, and
need for ravascularizationof the LAD in P treatad with PA compared with
tPA.
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What is the Ciinicai Outcome and Impact of
Ravascularization of TIMI 2 Flow Followina Acuts
Myocardiai Infarction?
G.R. McKendall, E.M. Antman, E. Braunwald, M.J. McDonald,
D.O. Williams for the TIMI 96 Investigators. Rhode /s/and Hospita/,
Providence, R\, USA, Brigham and Women3 Hospital, Boston, MA, USA
Although TIMI flow grade 2 (FG2) represents suboptimal reperfusion follow-
ing thrombolysis (T) for acute myocardiai infarction (AMI), the associated
clinical events and value of routine revascularization (REV) in such patienta
(pts) are unknown, We evaluated the clinical outcome of 328 pts treated with
either t-PA or streptokinase in TIMI 9B who had FG2 in their infarct related
arte~ during initial hospitalization. All pts (ALL) were followed for 30 to 80
days. The post discharge outcoma of ptstreatad with medical tharapy (MED,
n = 110, 34%) was compared to pts treated with REV during initial hospital-
ization (n= 218, S&%).Of pts traated with REV,19% had CABG and 81% had
PTCA (successful in 87% and partially successful in 7%), Baseline clinical
and hemodynamic characteristics were similar in both groups. in hospital
mortality was 8 (3.7%) and 1 (0.9%) for REV and MED (p= 0.137).
ClinicalOutcomeFromDischargeThrough60 Days
ALL n (%) REV n (%) MED n (%) p
Death 4 (1.3) 1 (0.5”/0) 3 (2.s”/.) 0.118
ReMl 1S (6”/0) s (4”/.) 10 (9°/6) 0,050
CHF 2 (0.60/.) 2 (l%) o (0”/0) o.43t
Angina 69(22”/0) 37(1s%) 32 (29%) 0.017
Readmissionforcardiscevent 61(t9%) 30(14”/0) 31 [2s%) 0.003
REV during hospitalization in pts with FG2 following T reduced subse-
quent ischemic avents after hospital diacharge.
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797-3 A Prospsctiva Multicsnter Triai Uaing the JJiS
Hsparin-Coated Stsnt for Primary Reperfueion of
Acuta Myocardial infarction
C.L. Grines, M.-C. Morice, L. Mattes, G.W. Stone, W. O’Neill, B. Firth,
E.G. Fernandez, F. Kiemeney, D. Jones, P.W.Serruys. William Baaumont
Hospital, Royal Oak, MI, USA, Thoraxcentec Rotterdam, Netherlands
Prtmaty stenting for acute myocerdial infarction is being performed with in-
creasing enthusiasm, however, due to concerns about stent thrombosis,
potent antiplatelet, anticoagulants and thrombdytic drugs have been admin-
istered to many patients, with resultant increase in hospital stay and cost.
The heperin-coated stent decreases platelet deposition by 95% compared
to an uncoated stent. We hypothesized that the heparin-coatad stent could
safely establish reperfusion, eliminate the need for post procedural anticoag-
ulation, and potentially reduce bleeding complications, ischemic events and
restenosis compared to other reperfusion strategies. In this 100 patient pilot
study, acute Ml patients are taken dire@lyto the catheterization laboreto~,
where prediiatation of the infarct-related vessel is performed. If the iumen
size is 23.0 mm, one or more heparin-coated stents are placad. If an optimal
stent result is achiaved (residual stenosis <10%, good flow, and absence
of residual filling defect or unstentad diasaction), no additional heparin ia
given. Thrombolytics, ReoPro and warfarin are avoidad. Clinical events are
monitored to 8 months, at which time follow-up angiography ia performed for
determination of reocclusion and restenosis rates. To date, 60 of the antici-
pated 100 patients hava been enrolled, and complete date will be available
by March of 1997. This pilot study will ba followed by a multicenter, inter-
national trial comparing the heparin-coated stent to prima~ PTCA for acute
myocerdial infarction.
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ml ~afstyandF~aSibilityOfPrimaf’y~enthIgin A.ute
Myocardiai infarction - In-hospital and 30 Day
Rssuits of tha PAMI Stent Pilot Trial
G.W. Stone, B. Brodie, J. Griffin, F.St. Gear, M.-C. Morice, C. Costantini,
p,A. overlie, D. Jones, W.W. O’Neill, C.L. Grines. The CafdiOVaSCU/af.
hrstitute, .E/Camino Hospital, Mountain View, CA, USA
Primay stenting in AMI has the potential to improva Iateoutcomes compared
to primary PTCA. A multicenter, prospective trial was therefore parformad
in which 300 pts with AMI underwent primary PTCA, followed by stenting
in all pts in the absence of contraindications. Pta were excluded only for
cerdiogenic shock and symptoms >12 hours. Major exclusions for stenting
were vessel size <2.75 mm, length 23 stents, giant thrombus, and the
expected inability to deliver or expand tha stent. Mean aga was 61 + 12
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n7975 Primary Stent Implantation Is Superior To BalloonAngioplasty In Acute Myocardisl Infarction - The
Result of Japanese PASTA(Primary Angioplaaty
Versus Stent Implantation In Acute Myocardial
Infarction) Trial
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of pta 41 43
Age 66+ 12 66+ 14 NS
Hoursfrom onset 5.2 + 3.6 4.9 i 3.4 NS
Successfulreperfusion ( ( 0
In-hospitalTLR* 1/40 (2,5%) 6/37 (16.2%)
In-hospitaldeath 2/41 (4.9”A) 5/43 (11/6°k.) NS
Clinicalsuccess 3s/41 (93”/0) 2S/43 (65”A) 0
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El7976 Sefety end feasibility of reacue PTCA or primery
PTCA in patients with acute myocardial infarction
admitted to a hoapital without PTCA facilities
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Thrombolysis Rescue PTCA Primary PTCA
N 36 38 39,.
( -59 l 10 y. 60+ 11 y. 59 i 10 y.
AnteriorMl 19 (53%) 24 (63%) 16 (46%)
Delay rend. 115 &60 min. 140 &60 min. 130 +70 min.
Delay angio 105 +30 min. 80 k 25 min.
Deoeaaed 1 (3%) 5 (13%) 2 (5”/6)
Recurrent Ml 3 ( 8%) 3 (6%) o
CABG/late PTCA 7 (19%) 4 (11”/0) 2 (5%)
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Classification of Unstable Angina
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Stable 95 5 5 17 15 5
Unstable ssore 3 60 7 13 30” 15 30”
score 4 6,*Q 36*E 43*Q 33* 54** 57*Q
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Thrombogenic Potentiel of Human Coronery
Atherosclerotic Plaques
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